

MGC Pharma GM Webinar

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), is pleased to confirm it will be hosting the General Meeting (GM) on **Thursday 2 July 2:30pm AWST** via a webinar.

The formal business of the GM will be hosted by MGC Pharma's Chairman, Brett Mitchell with all other Board members attending remotely.

To register for the webinar, please use the link below:

https://us02web.zoom.us/webinar/register/WN_yI71BNGtTyKEUWgweV4QWQ

Upon registration participants will be able to submit questions to the Company. The Board will endeavour to answer as many questions as possible regarding the Company's operations and future plans at the meeting.

--Ends--

Authorised for release by the Board, for further information please contact:

PR/IR Advisors – Media & Capital Partners

Melissa Hamilton (PR) +61 417 750 274

Rod Hinchcliffe (IR) +61 412 277 377

Melissa.Hamilton@mcpartners.com.au

Rod.Hinchcliffe@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390

info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    